AbCellera (NASDAQ:ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement data, during its first quarter 2026 earnings call on Monday, May 11, 2026.

ABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor (NK3R) for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. It is currently being evaluated in a Phase 1/2 study, and the results of the ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 portion in postmenopausal women with moderate-to-severe VMS are anticipated in Q3 2026.